Tilray Launches Medical Cannabis Products in Malta
Adobe Stock

Tilray Launches Medical Cannabis Products in Malta

The company’s medical cannabis division completes its first sales with products now available across the country.

Subscribe
February 17, 2022

LEAMINGTON, Ontario, Feb. 17, 2022 – PRESS RELEASE – Tilray Brands Inc., a leading global cannabis-lifestyle and consumer packaged goods company focused on inspiring and empowering the worldwide community to live its very best life, announced that its medical cannabis division, Tilray Medical, has completed its first sale of medical cannabis in Malta. Tilray’s EU-GMP medical cannabis products are now available in pharmacies across Malta, providing patients with safe and reliable access to high-quality medical cannabis.

Denise Faltischek, Tilray’s chief strategy officer and head of International Business, said, “As demand for cannabis continues to grow across Europe, we’re incredibly proud to partner with established and reliable distribution partners to supply new markets with high-quality medical cannabis which patients can rely on.”

In Malta, patients may obtain prescriptions for medical cannabis and a medical cannabis card through family doctors. Medical cannabis cards are issued by Malta’s Office of the Superintendence of Public Health.

Tilray has a pioneering track record as a company committed to making EU GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need around the world and was the first to successfully export medical cannabis from North America and import medical cannabis products into the EU in 2016.